Clinical Trial

A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male Subjects

Name: A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male Subjects — clinical trial record (NCT07400744)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The goal of this clinical study is to establish the comparability of the pharmacokinetics and similarity of the safety and immunogenicity profiles of QL2109 and Darzalex following a single intravenous infusion in healthy male subjects.

Trial Details

NCT Number	NCT07400744
Lead Sponsor	Qilu Pharmaceutical Co., Ltd.
Conditions	Multiple Myeloma
Enrollment	102 participants
Start Date	2026-03
Primary Completion	2026-09 (estimated)
Study Completion	2026-10 (estimated)
Updated on ClinicalTrials.gov	2026-02-10